The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

A CDC report set to be presented on June 26 at a meeting of the agency's Advisory Committee on Immunization Practices finds ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...